Buy Livagen (KEDA) Peptide Bioregulator

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source — scaled to whatever your research needs.

Scientific Research Context

What the published literature on Livagen examines. These are findings about the compound in the studies cited, not claims about the supplied material.

Protein synthesis in hepatocytes

In cultured rat hepatocytes of different ages, Livagen was reported to raise the rhythm and level of protein synthesis, with the largest effect in cells from old animals. Epitalon did not change it in the same system. [in vitro, rat cells]

Lymphocyte chromatin

In lymphocytes from elderly donors, Livagen was reported to decondense heterochromatin, including pericentromeric regions, and to activate ribosomal genes. Donor ages are not given in the abstract. [in vitro, human cells]

Enkephalin-degrading enzymes

Livagen inhibited enkephalin-degrading enzymes in human serum with an IC50 of 20 µM, against 500 µM for Epitalon, and did not interact with mu or delta opioid receptors in rat brain membranes. [in vitro]

Liver explants and digestive enzymes

Livagen was reported to stimulate growth of rat liver explants in organotypic culture. In rats given it by mouth for two weeks, digestive-enzyme activity fell in young animals and rose in old ones; small-intestine peptide hydrolases did not break it down. [ex vivo and animal, rat]

Overview

In short: Livagen (Lys-Glu-Asp-Ala, "KEDA") is a four-residue synthetic peptide from the Khavinson bioregulator family, studied in hepatocyte cultures, liver explants and lymphocyte chromatin assays.

Key research facts

Synthetic Lys-Glu-Asp-Ala (KEDA) tetrapeptide from the Khavinson short-peptide lineage

Designed from liver polypeptide preparations and paired with liver tissue

Studied for protein synthesis in cultured rat hepatocytes of different ages

Examined for chromatin decondensation in lymphocytes from elderly donors

Characterised against enkephalin-degrading enzymes, with Epitalon as comparator

These points summarise lab themes, not human outcomes.

KEDA is Vesugen (Lys-Glu-Asp) with an alanine added at the end. The programme's tissue-matching scheme gives each short peptide an organ, and Livagen is the liver peptide, set beside Cortagen for cortex, Epitalon for subcortical structures and Vilon for thymus. A 2001 paper reports that each of the four stimulated growth of explants from its matching tissue.

The experiments are cell and tissue based. In cultured rat hepatocytes, Livagen was reported to raise protein synthesis in cells of several ages, most in cells from old animals, while Epitalon did not change it in the same system. In lymphocytes from elderly donors it was reported to decondense heterochromatin and activate ribosomal genes. Against human serum enzymes, it inhibited enkephalin-degrading activity at an IC50 of 20 µM compared with 500 µM for Epitalon, with no interaction at opioid receptors in rat brain membranes. A secondary review summarises further animal work on liver models, which is not reproduced here.

It is supplied here as a lyophilised research powder for in-vitro and preclinical use. No analytical report for the supplied material has been published yet, so this page quotes no purity figure.

Research class: Synthetic short-peptide bioregulator (Khavinson family)

Sequence: Lys-Glu-Asp-Ala (KEDA)

Research focus: Hepatocyte and liver-explant cultures; lymphocyte chromatin; digestive enzymes in rats

Evidence base: Cell-culture, tissue and rat studies from one St. Petersburg lineage and a Tbilisi group; no human trial

Proposed Mechanism

Livagen is studied as a liver-matched short-peptide modulator of protein synthesis and chromatin state. The proposed model is nuclear uptake and chromatin binding; the evidence is culture-level and the human-cell data are cytogenetic.

Pathway Effect Why it matters Protein-synthesis rhythm Raised in cultured rat hepatocytes, most in cells from old rats The nearest thing to a functional liver readout; not reproduced elsewhere Heterochromatin decondensation Pericentromeric heterochromatin loosened and ribosomal genes activated in elderly-donor lymphocytes A cytogenetic endpoint; its meaning for gene expression is the authors' interpretation Peptidase interaction Inhibited enkephalin-degrading enzymes in serum; no opioid-receptor interaction A pharmacological property separate from the gene-regulation model Gut stability Not hydrolysed by rat small-intestine peptide hydrolases in vitro Relevant to why oral administration was studied in rats; no bioavailability data

Deeper dive for scientific readers

The Khavinson hypothesis is that ultrashort peptides regulate gene expression in a tissue-specific way, and Livagen is the liver case. The evidence assembled here is a mixture: hepatocyte and explant culture, a cytogenetic assay on human lymphocytes, an enzyme-inhibition assay, and a rat digestive-enzyme study. None of these measures liver gene expression directly. The review that summarises hepatitis, fibrosis and cirrhosis models in animals is a secondary source and its outcomes are not reproduced. A 2021 systematic review by the same group that lists many short peptides does not mention Livagen.

Common Questions People Are Asking

What is Livagen?

Livagen is the name used for the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA), developed in the Khavinson short-peptide programme and paired with liver tissue. It is supplied here as a laboratory research powder only.

How is Livagen related to Vesugen?

The first three residues of Livagen (Lys-Glu-Asp) are the sequence of Vesugen. Livagen adds an alanine. The literature does not state a derivation between them; the relationship here is a sequence observation, not a published claim.

What does the research on Livagen show?

In cultured rat hepatocytes it was reported to raise protein synthesis, most in cells from old animals. In lymphocytes from elderly donors it was reported to decondense heterochromatin. It also inhibited enkephalin-degrading enzymes in serum. All of it is preclinical or in vitro and from the originating lineage and a Tbilisi group.

Is there a Certificate of Analysis for Livagen?

Not yet. No independent analytical report has been published for this material, so no purity figure is quoted.

Is there human data on Livagen?

The human-cell work is in vitro on lymphocytes. No interventional human study was found. Livagen is sold strictly for in-vitro and preclinical research, not for human or veterinary use.

Where can I buy Livagen?

Right here - Livagen is supplied directly by New-U Research Compounds on this page, as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does Livagen cost?

Livagen pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Shipping is free on orders over $350.

How do I buy Livagen?

Add the Livagen pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy Livagen?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Is it legal to buy Livagen?

In the United States, Livagen is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Notes Laboratory research material. No human dosing exists for this compound and none is published or recommended here.

Evidence Tier

Overall: Tier 3: Limited / anecdotal

Livagen has a preclinical record with no interventional human trial among the abstracts reviewed. The studies are in cells, explants and rats from the originating institute and a Tbilisi group, and none has been replicated independently. It is supplied as unapproved laboratory material.

Tier 2 · Animal

Digestive-enzyme activity in the gastrointestinal tract and other organs of young and old rats after two weeks of oral administration

Growth of rat liver explants in organotypic culture

Databases & peer-reviewed sources

Last reviewed: 13 October 2026 · New-U Research Compounds

Khavinson VKh, Lezhava TA, Monaselidze JG, et al. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med 2002. · 2002 · PMID: 12533768 · DOI: 10.1023/a:1021924702103

Brodskii VIa, Khavinson VKh, Zolotarev IuA, et al. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izv Akad Nauk Ser Biol. · PMID: 15926314

Khavinson VK. Tissue-specific effects of peptides. Bull Exp Biol Med 2001. · 2001 · PMID: 11713572 · DOI: 10.1023/a:1013058701974

Kost NV, Sokolov OIu, Gabaeva MV, et al. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izv Akad Nauk Ser Biol 2003. · 2003 · PMID: 12942748

Timofeeva NM, Khavinson VKh, Malinin VV, et al. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Adv Gerontol 2005. · 2005 · PMID: 16075683

Riadnova IIu, Filippov SV, Iuzhakov VV. Functional morphology of an organotypic liver culture exposed to the peptide livagen. Adv Gerontol 2002. · 2002 · PMID: 12577697

Kuznik BI, Khasanova NB, Ryzhak GA, et al. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Adv Gerontol 2020. · 2020 · PMID: 32362099

PubMed: peer-reviewed literature on Livagen

ClinicalTrials.gov: registered studies on Livagen

Livagen: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Four-residue peptide: Lys-Glu-Asp-Ala (KEDA)

Vesugen (Lys-Glu-Asp) plus a C-terminal alanine

Liver-matched member of the Khavinson short-peptide family

Hepatocyte, explant, lymphocyte-chromatin and enzyme-inhibition studies

No interventional human trial; one research lineage

Supplied as 10 × 20 mg lyophilised vials; no analytical report published yet

Specifications

Sequence Lys-Glu-Asp-Ala (KEDA) Residues 4 Molecular Formula C 18 H 31 N 5 O 9 Molecular Weight 461.47 Da (average, free peptide) Form Lyophilised powder Pack 10 vials × 20 mg Family Khavinson short-peptide bioregulator Analytical report None published yet Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About Livagen (KEDA): Short-Peptide Bioregulator Research Guide

The patent behind Livagen (US 7,101,854 B2) has a priority date in October 2000 and was granted in 2006. The first paper to name the peptide, a short 2001 note on tissue-specific effects of peptides, dates to August of the following year. A Russian-language abstract renders the name as "lyvagen"; it is the same compound.

Livagen is Lys-Glu-Asp-Ala, not Lys-Glu-Asp-Pro, which is Prostamax. The formula C18H31N5O9 and average mass of 461.47 Da on this page are computed from the sequence and match the compound record.

New-U Research Compounds supplies Livagen as a lyophilised research powder in sealed 10-vial packs of 20 mg vials. No analytical report for the supplied material has been published yet, and this page makes no purity or certificate claim. It is for in-vitro and preclinical research only and nothing here is medical advice.

Khavinson VKh, Lezhava TA, Monaselidze JG, et al. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med 2002.

Brodskii VIa, Khavinson VKh, Zolotarev IuA, et al. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izv Akad Nauk Ser Biol.

Khavinson VK. Tissue-specific effects of peptides. Bull Exp Biol Med 2001.

Kost NV, Sokolov OIu, Gabaeva MV, et al. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izv Akad Nauk Ser Biol 2003.

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic / Longevity

Metabolic / Longevity MOTS-C MOTS-c mitochondrial-derived peptide activates AMPK via folate-AICAR pathway to regulate glucose metabolism, insulin sensitivity, and lipid oxidation. MOTS-C →

Metabolic / Longevity 5-Amino-1MQ 5-Amino-1MQ is a selective NNMT inhibitor that preserves intracellular NAD+ and SAM pools by blocking nicotinamide methylation in adipose tissue. 5-Amino-1MQ →

Metabolic / Longevity Epitalon Epitalon (AEDG) is a synthetic tetrapeptide telomerase activator that upregulates hTERT expression to elongate telomeres in human somatic cells. Epitalon →

Metabolic / Longevity FOXO4-DRI FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupts the FOXO4-p53 nuclear interaction to selectively induce apoptosis in senescent cells. FOXO4-DRI →

Metabolic / Longevity SS-31 SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane, binds cardiolipin, and restores electron transport chain efficiency in models of mitochondrial dysfunction. SS-31 →

Metabolic / Longevity Cartalax Cartalax (Ala-Glu-Asp / AED) is a synthetic short-peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell cultures. Cartalax →

Livagen vs related Metabolic / Longevity compounds

Compound Price Purity spec COA Livagen from $230 Not published On request MOTS-C from $156 >99% HPLC 2 published batches 5-Amino-1MQ from $93 >99% HPLC On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Livagen

Metabolic Research research compounds

Livagen research guide

Research this compound

Research guide Livagen research guide Livagen is studied as a liver-matched short-peptide modulator of protein synthesis and chromatin state. Read the guide →

Part of the Cognitive & longevity research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research